Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

Open access

Abstract

Background Patients with homozygous familial hypercholesterolemia (HoFH) respond inadequately to existing drugs. We conducted a phase 3 study to assess the efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in adults with HoFH. Methods Twenty-nine subjects enrolled into a single-arm, open-label study and maintained current lipid lowering therapy from six weeks before baseline through at least week 26. Lomitapide dose was escalated based on safety and tolerability from 5 mg to a maximum of 60 mg/day. The primary endpoint was mean percent change from baseline in LDL-C at week 26, after which patients remained on lomitapide through week 78 for safety assessment. Findings Twenty-three subjects completed weeks 26 and 78. The median dose of lomitapide was 40 mg/day. LDL-C was reduced by 50% from baseline at week 26 (4·3 ± 2·5 mmol/L vs. 8·7 ± 2·9 mmol/L, p<0.0001). Eight subjects achieved LDL-C <2·6 mmol/L at this time point. LDL-C was reduced by 44% at week 56 and 38% at week 78 (p<0.0001 for both). Gastrointestinal symptoms were the most common adverse event. Four patients had aminotransaminase > 5× ULN that resolved after dose reduction or temporary interruption of lomitapide. No subject permanently discontinued treatment due to liver abnormalities. Liver fat content assessed by nuclear magnetic resonance spectroscopy (NMRS; n=20) was 1·0 ± 1·3 % at baseline, 8·6 ± 8·1% at week 26 and remained stable up to week 78 (8·3± 5·3%). Interpretation These data demonstrate that lomitapide had a robust and durable efficacy in lowering LDL-C in patients with HoFH with an acceptable safety and tolerability profile.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(12)61731-0

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 744

Metadata

Authors
Cuchel, M., Meagher, E. A., du Toit Theron, H., Blom, D. J., Marais, A. D., Hegele, R. A., Averna, M. R., Sirtori, C. R., Shah, P. K., Gaudet, D., Stefanutti, C., Vigna, G. B., Du Plessis, A. M., Propert, K. J., Sasiela, W. J., Bloedon, L. T., & Rader, D. J.
Affiliations
  • University of Pennsylvania (US)
  • South African Medical Research Council (ZA)
  • Western University (CA)
  • University of Palermo (IT)
  • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
  • Cedars-Sinai Medical Center (US)
  • Université de Montréal (CA)
  • Sapienza University of Rome (IT)
  • University of Ferrara (IT)
  • Aegerion Pharmaceuticals (United States) (US)
Corresponding author
Cuchel, Marina
Venue
The Lancet
Publisher
Elsevier BV
Published
2013-01
Volume
381
Issue
9860
Pages
40-46
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2102238081
Cited by
744
References
27
Citations by year
2026: 36 · 2025: 28 · 2024: 50 · 2023: 40 · 2022: 50 · 2021: 38 · 2020: 34 · 2019: 45 · 2018: 34 · 2017: 60 · 2016: 73 · 2015: 87 · 2014: 97 · 2013: 66
FWCI
82.05
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
  • UpSpace Institutional Repository (University of Pretoria) (submittedVersion)
  • Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion, other-oa)
Funders
  • National Institutes of Health (UL1TR000003)
  • National Center for Research Resources (UL1RR024134)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
homozygous familial hypercholesterolemia, lomitapide, microsomal triglyceride transfer protein inhibitor, LDL cholesterol lowering, lipid-lowering therapy, aminotransferase elevation, gastrointestinal adverse effects, drug safety, drug efficacy, dose escalation, liver function monitoring, LDL receptor deficiency
MeSH terms
Benzimidazoles, Carrier Proteins, Female, Homozygote, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Male

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. https://app.cochat.ai/papers/10.1016/s0140-6736(12)61731-0
The paper
Cuchel, M., Meagher, E. A., du Toit Theron, H., Blom, D. J., Marais, A. D., Hegele, R. A., Averna, M. R., Sirtori, C. R., Shah, P. K., Gaudet, D., Stefanutti, C., Vigna, G. B., Du Plessis, A. M., Propert, K. J., Sasiela, W. J., Bloedon, L. T., & Rader, D. J. (2013). Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. The Lancet. https://doi.org/10.1016/s0140-6736(12)61731-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.